• Veyonda clinical program continuing on plan
• Imminent release of interim DARRT-1 clinical data
• DARRT program to be expanded and expedited based on early data
• LuPIN-1 data to be released mid-year
• Major opportunity identified for Veyonda in growing radiopharmaceutical use
• Strategic review prompted by increasing commercial opportunities
• Continuing emphasis on value creation of IP.
Sydney, 29 January 2019: Noxopharm (ASX:NOX) today releases its Appendix 4C for the quarter ended 31 December 2018, as well as providing guidance for the next 12 months. This report is for the Noxopharm group covering both NOX and its majority-owned subsidiary, Nyrada Inc.
For further information please download PDF attached:
Download this document
